- Home
- CPT vs BMRN Comparison
CPT vs BMRN Comparison
Compare CPT & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPT
- BMRN
- Stock Information
- Founded
- CPT 1993
- BMRN 1996
- Country
- CPT United States
- BMRN United States
- Employees
- CPT N/A
- BMRN N/A
- Industry
- CPT Real Estate Investment Trusts
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- CPT Real Estate
- BMRN Health Care
- Exchange
- CPT Nasdaq
- BMRN Nasdaq
- Market Cap
- CPT 12.2B
- BMRN 12.1B
- IPO Year
- CPT 1993
- BMRN 1999
- Fundamental
- Price
- CPT $118.26
- BMRN $58.86
- Analyst Decision
- CPT Buy
- BMRN Buy
- Analyst Count
- CPT 19
- BMRN 22
- Target Price
- CPT $128.55
- BMRN $93.43
- AVG Volume (30 Days)
- CPT 972.9K
- BMRN 1.6M
- Earning Date
- CPT 05-01-2025
- BMRN 05-01-2025
- Dividend Yield
- CPT 3.55%
- BMRN N/A
- EPS Growth
- CPT N/A
- BMRN 152.82
- EPS
- CPT 1.09
- BMRN 2.71
- Revenue
- CPT $1,562,268,000.00
- BMRN $2,950,227,000.00
- Revenue This Year
- CPT $2.10
- BMRN $12.27
- Revenue Next Year
- CPT $3.59
- BMRN $9.86
- P/E Ratio
- CPT $108.82
- BMRN $21.79
- Revenue Growth
- CPT 0.55
- BMRN 19.36
- 52 Week Low
- CPT $98.35
- BMRN $52.93
- 52 Week High
- CPT $127.69
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- CPT 54.42
- BMRN 37.63
- Support Level
- CPT $118.20
- BMRN $58.74
- Resistance Level
- CPT $120.15
- BMRN $61.26
- Average True Range (ATR)
- CPT 2.13
- BMRN 1.98
- MACD
- CPT 0.72
- BMRN -0.03
- Stochastic Oscillator
- CPT 61.81
- BMRN 1.80
About CPT Camden Property Trust
Camden Property Trust is a real estate investment trust engaged in the ownership, management, development, reposition, redevelopment, acquisition, and construction of multifamily apartment communities. It owned interests in, operated, or developing nearly 177 multifamily properties comprised of nearly 59,996 apartment homes across the United States.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.